Naturally occurring substitutions of conserved residues in human immunodeficiency virus type 1 variants of different clades are involved in PG9 and PG16 resistance to neutralization
- 1 July 2012
- journal article
- research article
- Published by Microbiology Society in Journal of General Virology
- Vol. 93 (7) , 1495-1505
- https://doi.org/10.1099/vir.0.042614-0
Abstract
The recently described anti-human immunodeficiency virus type 1 (HIV-1) human mAb PG9 and PG16 are cross-clade broadly neutralizing. Therefore, it can be postulated that the targeted epitope(s) are highly conserved among variants of the entire group M. We analysed the sensitivity to PG9 and PG16 of pseudotyped viruses carrying envelope glycoproteins from the viral quasispecies of three HIV-1 clade CRF01_AE-infected patients. The broad heterogeneity in sensitivity to PG9 and PG16, despite closely genetically related envelope glycoproteins issued from single individuals, allowed us to identify two gp120 cross-clade conserved residues, a lysine at position 168 in the V2 loop and an isoleucine at position 215 in the C2 region, whose substitutions were associated with resistance to PG9 and PG16. By site-directed mutagenesis, we confirmed both in clades B and CRF01_AE that the substitutions K168E and I215M have a major impact on PG9 and PG16 neutralization sensitivity of pseudotyped viruses.Keywords
This publication has 36 references indexed in Scilit:
- Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9Nature, 2011
- Broad neutralization coverage of HIV by multiple highly potent antibodiesNature, 2011
- Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibodyProceedings of the National Academy of Sciences, 2011
- Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01Science, 2010
- Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1Science, 2010
- Rational antibody-based HIV-1 vaccine design: current approaches and future directionsCurrent Opinion in Immunology, 2010
- Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine TargetScience, 2009
- Challenges in the development of an HIV-1 vaccineNature, 2008
- Molecular architecture of native HIV-1 gp120 trimersNature, 2008
- Broad HIV-1 neutralization mediated by CD4-binding site antibodiesNature Medicine, 2007